Quality-by-Design-Driven Development, Optimization, and Evaluation of a Thermoresponsive Intranasal Bosutinib In Situ Gel for Enhanced Nose-to-Brain Delivery
This study utilized a Quality-by-Design approach to develop and optimize a thermoresponsive, mucoadhesive intranasal in situ gel containing Bosutinib, which successfully demonstrated enhanced nose-to-brain delivery potential and preserved cytotoxic activity against triple-negative breast cancer cells.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
The human brain is a fortress, protected by a highly selective wall known as the blood-brain barrier. This natural defense system filters the blood, allowing essential nutrients to pass while blocking most foreign substances, including many life-saving medicines. While this protection is vital for health, it creates a significant hurdle for treating cancers that spread to the brain, such as triple-negative breast cancer. This aggressive form of cancer often travels to the brain, where standard drugs struggle to penetrate the barrier in sufficient quantities to be effective. To bypass this obstacle, scientists have turned their attention to the nose. The nasal cavity offers a direct, non-invasive pathway to the brain, allowing medications to travel along nerve pathways that ignore the blood-brain barrier. However, simply spraying a liquid into the nose is often ineffective because the body's natural cleaning mechanisms quickly wash the medicine away before it can take hold. To solve this, researchers are developing smart gels that remain liquid when cool but transform into a sticky gel at body temperature, allowing the drug to stay in place long enough to work.
In a recent study, a team of researchers at GITAM University in India set out to create such a delivery system for bosutinib, a drug used to treat certain types of cancer. While bosutinib shows promise against triple-negative breast cancer, it has difficulty dissolving in water and cannot easily cross into the brain on its own. The researchers aimed to package this drug into a thermoresponsive, mucoadhesive nasal gel. In plain terms, this means they created a liquid mixture that turns into a gel when it touches the warmth of the nose and sticks to the nasal lining. They used two specific ingredients to achieve this: poloxamer 407, which causes the liquid to turn into a gel when warmed, and carbopol 934, which helps the gel stick to the tissue. By combining these, they hoped to trap the drug in the nose, allowing it to slowly release and travel directly to the brain.
To find the perfect recipe, the scientists did not guess; they used a precise statistical method called a central composite design. This approach allowed them to test how different amounts of the two polymers and different mixing times affected the final product. They were looking for a specific balance: the gel needed to form at the right temperature, roughly matching the warmth of the human nose, and it needed to release the drug slowly over time rather than all at once. After running numerous experiments, they identified an optimal mixture containing 17.04 percent poloxamer and 0.1 percent carbopol, mixed for 15 minutes. This specific combination produced a clear, transparent liquid at room temperature that transformed into a firm, sticky gel when warmed to body temperature. The resulting gel formed in about 30 seconds and maintained a pH level of 6.3, which is gentle enough not to irritate the sensitive tissues inside the nose.
The researchers then put this optimized gel through a series of rigorous tests to ensure it was safe and effective. They confirmed that the drug did not chemically react with the gel ingredients in a harmful way, meaning the medicine remained stable and intact within the mixture. When they tested how the gel behaved under a microscope, they saw a dense, three-dimensional network of fibers, a structure that explained why the gel could hold the drug and stick to the nasal lining. In tests simulating the human nose, the gel released the drug in a controlled manner. While a simple liquid suspension of the drug released only a tiny fraction of its content over three days, the gel released 73 percent of the drug over the same period. This sustained release is crucial because it keeps the drug available for a longer time, increasing the chances it will reach the brain.
Perhaps the most encouraging finding came from testing the gel against cancer cells in a laboratory dish. The researchers used MDA-MB-231 cells, a model for the aggressive triple-negative breast cancer that often spreads to the brain. When they exposed these cells to the gel containing bosutinib, the drug proved significantly more effective at killing the cancer cells than the drug alone. The gel formulation reduced cell viability to an average of 3.87 percent at high concentrations, whereas the drug by itself failed to kill half the cells even at its highest tested dose. This suggests that the gel not only delivers the drug but may also help the cells absorb it more effectively. Furthermore, when they examined nasal tissue samples treated with the gel, they found no signs of damage or inflammation, indicating that the formulation is safe for the delicate tissues of the nose.
Despite these promising results, the researchers are careful to note that this work is a proof of concept. The study was conducted entirely in the laboratory and on tissue samples, without testing the gel in living animals or humans. While the gel successfully demonstrated the ability to hold the drug, release it slowly, and kill cancer cells in a dish, its actual ability to treat brain metastases in a patient remains to be seen. The team concludes that their thermoresponsive nasal gel represents a highly promising, non-invasive strategy for delivering bosutinib to the brain, offering a potential new path for managing brain-metastatic triple-negative breast cancer. Future studies will need to confirm whether this delivery system can effectively navigate the complex environment of a living body to reach its target.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.